Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B‑40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial - Bear, H D; Tang, G; Rastogi, P (Lancet Oncol, 2015)
et al.